FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 635 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... May 2, 2024 New Treatment Approach Could Help Prevent Recurrences of Some Bladder Cancers May 31, 2018 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs... September 27, 2019 Additional Translations of the ESMO Patient Guides Now Available in the Croatian May 18, 2026 Load more HOT NEWS HBV Infection Associated with Increased Risk of Primary Extrahepatic Malignancies Self-Dissolving Cracker Makes Swallowing Easier for People Struggling with Dysphagia Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... Coping With Life After a Bone Marrow Transplant: A Survivor’s Story
